Login / Signup

Survey of workflow and cost implications of decommissioning regarding the Falsified Medicines Directive in Hungarian hospital pharmacies.

Péter VajdaKatalin RichterZsolt BodrogiRóbert György VidaLajos BotzSándor KovácsAntal Tamás ZemplényiRichárd BellaAndrás Fittler
Published in: BMJ open (2021)
Notably, our research is the first complex study depicting FMD cost implications in the hospital pharmacy sector in Central Europe, indicating decommissioning significantly impacted workflow referencing human resources and IT.
Keyphrases
  • healthcare
  • endothelial cells
  • electronic health record
  • acute care
  • adverse drug
  • cross sectional
  • emergency department
  • induced pluripotent stem cells
  • pluripotent stem cells